Reinventing Membrane Imaging with BMI: A Better Way to Perform Particle Analysis

/by

Pharmaceutical companies go to great lengths to ensure the stability of their products. They test for it, they plan for it, they design around it. Why? Because stability is essential to the therapeutic success of a product. Without it, maintaining efficacy and safety would be impossible. Proteins are particularly susceptible to aggregation, and this can […]

Read more

Breaking the Bias: Women Leadership in Biotech

/by

There is a well-known saying that says, “behind every great man, there is a great woman.” This quote has never been more relevant than it is today in the biotech industry. Despite making up half of the population, women are severely underrepresented in leadership positions throughout the biotech sector. However, as we continue to battle […]

Read more

Light Obscuration May Not be Enough to Detect SVPs in your Drug Product

/by

Did you know that subvisible particles (SVPs) are the leading cause of drug product recalls? Despite being tiny, these particles have a big impact on biologic, cell, and gene therapies – not only limiting a product’s shelf life, but also comprising patient safety. For this reason, injectable drugs face strict requirements to be virtually free […]

Read more

Identifying Stable Biologic Candidates During CLD: Leveraging the Power of Immunoassays

/by

CHO cell line development (CLD) has revolutionized modern therapeutic antibody production due to their scalability benefits, ability to produce proteins with the necessary mammalian posttranslational modifications, and large yield protein titers.1 To meet the exponentially growing demand, CHO cell line developers have focused their attention on maximizing titer. However, newer and more complex biologic modalities […]

Read more